

# CANCER BIOMARKERS CONFERENCE III

[events.houstonmethodist.org/cancerbiomarkers](http://events.houstonmethodist.org/cancerbiomarkers)

## REGISTER NOW

**Saturday, Sept. 15, 2018**

7 a.m. – 6 p.m.

**Sunday, Sept. 16, 2018**

7 a.m. – Noon

Houston Methodist Research Institute  
6670 Bertner Ave.  
John F. Bookout Auditorium, 2nd Floor  
Houston, TX 77030

Also open for registration!

**CBCIII Bootcamp: A Field Guide for  
Pharmaceuticals and Diagnostics**

**Friday, Sept. 14, 2018**

Noon – 5 p.m.

**CBCIII Dinner Symposium**

**Saturday, Sept. 15, 2018**

7-9 p.m.

Houston Marriott Texas Medical Center

*(For more information, see page 4.)*

HOUSTON  
**Methodist**<sup>®</sup>  
LEADING MEDICINE

**Presented by**

Houston Methodist Department of  
Pathology and Genomic Medicine



## PROGRAM OVERVIEW

Since the last Cancer Biomarkers Conference, new tests have emerged for predictive biomarkers used to select cancer patients for new molecular-targeted therapies. New immune therapies for their cancer treatment have also emerged. New technologies, such as liquid biopsy, have advanced. Revised guidelines, as well as new guidelines have also been published.

Pathologists and oncologists need to know the answers to a host of questions in this rapidly developing field of biomarkers in order to offer the best patient care.

These questions include:

- Which cancer patients should have biomarker testing?
- Which biomarker tests should be done for a given patient?
- What tissue samples are appropriate for a given biomarker test?
- How should the biomarker tests be performed, and how should they be interpreted, reported and used for patient care?

## AGENDA ▪ Presentations and Speakers

### SATURDAY, SEPT. 15, 2018

8 a.m. **Keynote Presentation 1:  
The Oncologist's Approach to TKI Therapy**

**Bruce Johnson, MD, ASCO President**

Chief Clinical Research Officer,  
Dana-Farber Cancer Institute  
Harvard Medical School  
Boston, Massachusetts

8:30 **Current Approach to Using Cytology  
Specimens for Biomarker Testing**

**Sinchita Roy-Chowdhuri, MD, PhD**

Director, Molecular Cytopathology,  
MD Anderson Cancer Center  
University of Texas MD Anderson Cancer Center  
Houston, Texas

9 **Review on Application of NGS to  
Biomarker Testing**

**Neal Lindeman, MD**

Director, Center for Advanced Molecular Diagnostics,  
Brigham and Women's Hospital  
Harvard Medical School  
Boston, Massachusetts

9:30 **Regulation and Billing for Molecular Testing**

**Dara Aisner, MD**

Director, Colorado Molecular Correlates Laboratory,  
University of Colorado  
University of Colorado School of Medicine  
Aurora, Colorado

10 Break

10:30 **Biomarker Testing in Community Practice**

**Richard Brown, MD**

Medical Director, System Laboratory Services,  
Memorial Hermann Hospital System  
Houston, Texas

11 **Update on Endometrial Cancer  
Biomarker Testing**

**Teri Longacre, MD**

Director, Gynecologic Pathology,  
Stanford University Medical Center  
Stanford University School of Medicine  
Stanford, California

11:30 **Update on Breast Cancer Biomarker Testing**

**Deborah Dillon, MD, PhD**

Director, Breast Tissue Bank, Dana-Farber Cancer Institute,  
Harvard Medical School  
Boston, Massachusetts

Noon **Panel Discussion**

12:30 p.m. **Lunch and Keynote Presentation 2:  
Role of Preanalytics in Biomarker  
Development and Patient Care**

**Carolyn Compton, MD, PhD**

Professor of Life Sciences and Barrett Honors Faculty,  
Arizona State University  
Adjunct Professor of Pathology,  
Johns Hopkins Medical Institutions  
CMO, National Biomarker Development Alliance  
Tempe, Arizona

1 p.m. **Update on Upper Gastrointestinal Cancer  
Biomarker Testing**

**Kay Washington, MD, PhD**

Director, Gastrointestinal and Hepatic Pathology,  
Vanderbilt University Medical Center  
Vanderbilt University School of Medicine  
Nashville, Tennessee

2 **Update on Colon Cancer Biomarker Testing**

**Rhonda Yantiss, MD**

Director, Gastrointestinal and Liver Pathology Service,  
Weill Cornell Medicine  
Weill Cornell Medicine Medical College  
New York City, New York

2:30 **Update on HPV Head and Neck Squamous Cell Carcinoma Molecular Testing**

**Mary Schwartz, MD**

Jack L. Titus Chair in Pathology and Medical Director,  
Anatomic Pathology, Houston Methodist Hospital  
Baylor College of Medicine  
Houston, Texas

3 Break

3:30 **Update on Melanoma Biomarker Testing**

**Patricia Chevez-Barrios, MD**

Director, Ophthalmic Pathology Fellowship Program,  
Houston Methodist Hospital  
Weill Cornell Medicine Medical College  
Houston, Texas

4 **Update on Leukemia Biomarkers**

**Daniel Arber, MD**

Donald West and Mary Elizabeth King Professor  
Chairman, Department of Pathology,  
University of Chicago  
Chicago, Illinois

4:30 **Update on Lymphoma Biomarkers**

**Genevieve (Eve) Crane, MD, PhD**

Associate Director, Flow Cytometry Laboratory,  
University of Rochester Medical Center  
University of Rochester School of Medicine and Dentistry  
Rochester, New York

5 **Panel Discussion**

5:30 **Panel Discussion: Conceptual Considerations of Guidelines and Their Implications for Patients**

**SUNDAY, SEPT. 16, 2018**

8 a.m. **The Revised Lung Cancer Biomarker Guidelines**

**Neal Lindeman, MD**

Director, Center for Advanced Molecular Diagnostics,  
Brigham and Women's Hospital  
Harvard Medical School  
Boston, Massachusetts

8:30 **Liquid Biopsy**

**John Iafrate, MD, PhD**

Director, Center for Integrated Diagnostics,  
Massachusetts General Hospital  
Harvard Medical School  
Boston, Massachusetts

9 **Overview of PD-L1**

**Alain Borczuk, MD**

Vice Chairman for Anatomic Pathology,  
Weill Cornell Medical  
Director of Anatomic Pathology, Weill Cornell Medical  
Chief of Thoracic Pathology, Weill Cornell Medical  
New York City, New York

9:30 **Update on PD-L1 Testing for Lung Cancer**

**Mari Mino-Kenudson, MD**

Director, Pulmonary Pathology,  
Massachusetts General Hospital  
Harvard Medical School  
Boston, Massachusetts

10 Break

10:30 **Update on PD-L1 Testing for Urologic Cancers**

**Donna Hansel, MD, PhD**

Chief, Division of Anatomic Pathology,  
University of California San Diego  
Director, Hansel Laboratory,  
University of California San Diego  
San Diego, California

11 **Update on PD-L1 Testing for Melanoma**

**Janis Taube, MD**

Director, Division of Dermatopathology,  
The Johns Hopkins Hospital  
The Johns Hopkins University School of Medicine  
Baltimore, Maryland

11:30 **Update on Immune Therapy Biomarkers in Breast Cancer**

**Ashley Cimino Mathews, MD**

Director, Breast Pathology Program,  
The Johns Hopkins Hospital  
The Johns Hopkins University School of Medicine  
Baltimore, Maryland

Noon **Panel Discussion**

12:30 p.m. **Adjournment**

## DIRECTORS

### Program Director

Philip T. Cagle, MD, Houston Methodist Hospital

### Deputy Program Directors

Alain Borczuk, MD, Weill Cornell Medical College

Donna Hansel, MD, PhD, University of California, San Diego

Ross A. Miller, MD, Memorial Pathology Consultants, Houston

### Local Program Directors

Eric Bernicker, MD, Houston Methodist Hospital

Randall J. Olsen, MD, PhD, Houston Methodist Hospital

Sinchita Roy-Chowdhuri, MD, PhD, MD Anderson Cancer Center

### National Program Directors

Daniel Arber, MD, University of Chicago

Sanja Dacic, MD, PhD, University of Pittsburgh Medical Center

## EXECUTIVE BOARD

Mary R. Schwartz, MD, Houston Methodist Hospital, Chair

Mary Beth Beasley, MD, Mount Sinai, New York

David W. Bernard, MD, PhD, Houston Methodist Hospital

Stanley R. Hamilton, MD, PhD, MD Anderson Cancer Center

Dina R. Mody, MD, Houston Methodist Hospital

Luan D. Truong, MD, Houston Methodist Hospital

Lanjing Zhang, MD, Rutgers University

### Target Audience

Physicians, nurses, and residents/fellows will benefit from this course.

### Accreditation and Credit Designation Statements

#### **Physicians**

Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Houston Methodist designates this live activity for 13.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### **ABPath Maintenance of Certification**

This activity has been registered to offer credit in the American Board of Pathology's (ABPath) Maintenance of Certification program. This activity will provide up to 13 credits for ABPath Lifelong Learning (Part II).

#### **Nurses**

Houston Methodist is an approved provider of continuing nursing education by the Texas Nurses Association – Approver, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

Houston Methodist will provide X.X contact hours for this activity. Participants must attend sessions in their entirety and complete the evaluation tool.

## CBCIII Bootcamp\*

**Friday, Sept. 14 - Noon - 5 p.m.**  
**Houston Marriott Medical Center**

This half-day session preceding the formal Cancer Biomarkers Conference is designed chiefly for those pharmaceutical and IVD personnel at all levels who are involved in cancer biomarkers and companion diagnostics. Pathologists, oncologists and others with interest and responsibilities in these areas can also benefit from the unique perspectives of the session.

*\*Bootcamp is not certified for CME credit. Separate registration is required.*

## CBCIII Dinner Symposium

**Saturday, Sept. 15 - 7-9 p.m.**  
**Houston Marriott Medical Center**

This CME Dinner symposium will follow shortly after the Cancer Biomarkers Conference adjourns on Saturday evening. The session will focus on the integration of current biomarker testing into daily practice, to help practitioners develop insight into acceptable resource utilization with the goal of defining patient populations who benefit from biomarker testing.

## Cancer Biomarkers Conference Accommodations

**Houston Marriott Medical Center**  
**6580 Fannin St., Houston, TX 77030**

A limited block of rooms have been reserved until **Friday, August 17, 2018** at the discounted rate of **\$129/night**, or the block is filled. Visit the website to view more information and to book a room.